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Abstract 
Conventional dendrimers are spherical symmetrically branched polymers ending with active 
surface functional groups.  Polyamidoamine (PAMAM) dendrimers have been widely studied as 
gene delivery vectors and have proven effective at delivering DNA to cells in vitro.  However, 
higher generation (G4-G8) PAMAM dendrimers exhibit toxicity due to their high cationic charge 
density and this has limited their application in vitro and in vivo.  Another limitation arises when 
attempts are made to functionalize spherical dendrimers as targeting moieties cannot be site-
specifically attached.  Therefore, we propose that lower generation asymmetric dendrimers, 
which are likely devoid of toxicity and to which site-specific attachment of targeting ligands can 
be achieved, would be a viable alternative to currently-available dendrimers.  We synthesized 
and characterized a series of peptide-based asymmetric dendrimers and compared their toxicity 
profile and ability to condense DNA to spherical PAMAM G1 dendrimers.  We show that 
asymmetric dendrimers are minimally toxic and condense DNA into stable toroids which have 
been reported necessary for efficient cell transfection.  This paves the way for these systems to 
be conjugated with targeting ligands for gene delivery in vitro and in vivo.   
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Introduction 
Dendrimers such as polyamidoamine (PAMAM) [1], polyethyleneimine (PEI) [2] and poly(L-
lysine) (PLL) [3] have been used to facilitate delivery and expression of DNA [4], delivery of 
drugs and radiotherapeutics [5,6] and for in vitro and in vivo diagnostics [7].  Dendrimers are 
synthesized by either divergent [8] or convergent [9] approaches, each of which can give rise to 
linear or branched architectures, thus enabling the size and generation of the dendrimer to be 
controlled during synthesis.  Commercially-available dendrimers such as PAMAM and PEI are 
formed in solution by sequentially coupling ‘layers’ of repeating branched monomer units 
starting from a central core and ending with NH2, OH, CHO, COOMe, Boc, COONa or CH3 
termini, the NH2 typically being employed in gene delivery.  The surface amine groups of 
PAMAM and other dendrimers interact with negatively charged molecules (e.g. DNA, 
oligonucleotide, siRNA) allowing dendrimers to protect and  transport these molecules to a wide 
variety of cell types (reviewed in [10]). 
Of spherical dendrimers, PAMAM is the most widely used for in vitro gene delivery, with the 
primary focus being on the use of highly-branched (‘high generation’ G4 – G8) dendrimers 
which are predicted to possess between 64 and 1024 surface amine termini [1,11,12].  High 
generation PAMAM dendrimers have been found to facilitate more efficient transfection than the 
lower generation dendrimers.  For example, in vitro studies performed using PAMAM G6 
dendrimers showed maximal transfection whereas use of G10 dendrimers provided no significant 
increase in transfection efficiency [13] and PAMAM G2 dendrimers facilitate negligible plasmid 
DNA transfection relative to G4, G7 and G9 dendrimers [14].  PAMAM dendrimers modified 
with PEG or cyclodextrins have also been used to successfully achieve high transfection 
efficiency in vitro (reviewed in [15]). 
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Despite these results a major shortcoming of PAMAM dendrimers, that limits their use both in 
vitro and in vivo has been undesirable toxicity associated with their high surface cationic charge 
density and the excess positive charge associated with the high Nitrogen (dendrimer):Phosphate 
(DNA) ratios commonly employed [11,12].  For PAMAM dendrimers in vitro, toxicity has been 
shown to be generation-dependent with the G5 and G7 higher generation dendrimers exhibiting 
increasing cytotoxicity over G3 dendrimers [11] and higher-generation (≥ G4) PAMAM 
dendrimers are approximately three-fold more cytotoxic than G2 or G3 dendrimers [1].  Surface 
PEGylation of spherical dendrimers has been attempted to circumvent toxicity however, this has 
led to a reduced number of surface sites available for drug/gene conjugation/complexation 
[16,17].  For targeted delivery of DNA, another limitation of spherical PAMAM dendrimers is 
that there is a surplus of available reactive sites due to the stochastic synthesis.  Therefore it is 
not possible to attach targeting ligands in a site-specific manner or distal to the DNA-complexing 
sites.  Furthermore, PAMAM dendrimers are relatively expensive to manufacture, primarily due 
to the significant excess of monomer units required for traditional growth schemes, and the 
reduced purity of the desired end product obtained relative to solid phase synthesis [18].   
One approach to overcoming the limitations of spherical dendrimers would be development of 
low-generation, asymmetric dendrimers that could be prepared on an insoluble solid-support, for 
example, by a technique commonly referred to as solid phase peptide synthesis (SPPS) [19-21].  
One advantage of SPPS is that low-generation asymmetric dendrimers can be synthesized 
rapidly, in high purity and yield [20,22].  We propose the low cationic charge of such 
dendrimers, even at high N:P ratios, would not predispose them to the cytotoxicity observed with 
higher generation spherical dendrimers.  By utilizing the well-established technique of SPPS, 
asymmetric dendrimers could be readily constructed to incorporate a well defined site for a 
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targeting-ligand, using an orthogonal protecting strategy where a targeting-ligand is site-
specifically conjugated on a side-chain of the dendrimer distal to the DNA binding site [23].  
Targeting moieties could be as diverse as antibodies [24], peptides  and carbohydrates [25], 
(reviewed in [26]) depending on the target-cell of interest.   
Here we describe an approach, using SPPS, for rapid synthesis of peptide-based low-generation 
asymmetric dendrimers.  The physico-chemical characteristics of dendrimer-DNA binding, 
toxicity profile and morphology were compared for dendrimer/DNA complexes formed using 
either peptide-based asymmetric dendrimers or a commercially-available PAMAM G1 
dendrimer, for comparison.  
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Materials and Methods 
Materials 
All fluorenylmethyloxycarbonyl (Fmoc) amino acids and Rink amide resin (200-400 mesh) were 
purchased from NovaBiochem (Australia) unless otherwise stated.  The solvent employed 
throughout the synthesis was peptide grade N, N-Dimethylformamide (DMF; Merck) used 
without further purification.  PAMAM G1, piperidine, trifluoroacetic acid (TFA) and ethidium 
bromide were purchased from Sigma-Aldrich.  Dulbecco’s modified Eagle’s medium (DMEM) 
and Lipofectamine
®
 were purchased from Invitrogen.   
Instrumentation  
Purification of asymmetric dendrimers was performed by reverse-phase high performance liquid 
chromatography (RP-HPLC).  Preparative RP-HPLC was performed on a Waters HPLC system 
(Model 600 controller, 2996 photodiode array detector) with a C4 column (Vydac, 5 μm pore 
size, id = 4.6 mm, 250 mm).  Dendrimers were injected (~100 mg/batch) using a flow rate of 10 
ml/min, isocratic conditions (100 % A) and purified with the mobile phase comprising solvent A 
(100 % H2O), solvent B (90 % CH3CN(aq)).   
Analytical RP-HPLC was performed using a Shimadzu HPLC system (controller- CBM-20A, 
pump A - LC-10AD, autosampler – SIL-10AXL, detector – SPD-10A) with a C4 column and 
mobile phase comprised solvent A (0.02 % HFBA(aq)) [27] and solvent B (90 % CH3CN(aq)).  
Analysis of each purified asymmetric dendrimer was undertaken at a flow rate of 1 ml/min, using 
the following conditions: 100 % A (0-20 min), then to 100 % B linearly over 10 min.    
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Liquid chromatography/mass spectrometry (LC-MS) was performed using an Applied 
Biosystems/MDS Sciex Q-TRAP LC/MS/MS system.  For ESI
+
-MS, each asymmetric 
dendrimer was dissolved in 50 % CH3CN(aq) to 300 μg/ml and observed for the molecular ion.  
NMR spectroscopy was performed using a Bruker Topsin 400/500 NMR spectrometer 
(400/500MHz).  Each asymmetric dendrimer was dissolved in D2O with one or two drops of 
dioxane as an internal reference for 
13
C NMR and dendrimer assignments confirmed with the aid 
of 1D and 2D NMR. 
Asymmetric dendrimer synthesis 
Asymmetric dendrimers were synthesized as previously described [28], on a 0.5 mmol scale 
using Fmoc SPPS [20,29].  Rink amide resin (0.6 mmol/g loading capacity) was swollen in DMF 
in a sintered glass vessel for 60 min followed by Fmoc deprotection with 20 % v/v piperidine in 
DMF (2 × 8 min washes).  All amino acids were pre-activated prior to coupling using O-
benzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU; 0.5 M in DMF) 
and N, N-diisopropylethylamine (DIPEA).  Each coupling step was monitored for ninhydrin 
values of ≥ 99 % using a quantitative colour test devised to detect the presence of free amino 
groups spectrophotometrically [30], the Fmoc group was then deprotected as outlined above.  
The Rink amide resin was treated with Fmoc-protected amino acids (except for arginine which is 
both Fmoc and Pbf protected) in the following sequence: 
4
+
 Arginine (Figure. 1-2): Glycine (Gly) (3 equiv), Gly (2 equiv), Gly (2 equiv), Lysine (Lys) (2 
equiv), Arginine (Arg) (5 equiv).  Terminal Fmoc protected groups were deprotected using 20 % 
v/v piperidine in DMF, the resin was then washed with DCM and dried in vacuo.  The Pbf 
protecting group was removed during acidolytic cleavage of the dendrimers off-resin using 
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TFA:DCM:H2O:TIPS (90:5:2.5:2.5; 3 h).  The mixture was filtered and TFA removed in vacuo.  
The mixture was then co-evaporated with toluene (3 × 15 ml), and triturated with ice cold diethyl 
ether.  The dendrimer (crude) was reconstituted in water and lyophilized.  
1
H NMR (D2O) δ 
(ppm): 1.30 – 1.85 (Rβ, R1β, Kβ, Kδ , Rγ, R1γ, Kγ, CH2, 14H, m), 3.09 – 3.17 (Rδ, R1δ, Kδ, 
CH2, 6H, m), 3.76 – 3.93 (Rα, CH, G1-2α, Gα, CH2, 7H, m), 3.96 – 3.99 (R1α, CH, 1H, t, J = 6.61 
Hz), 4.21 – 4.24 (Kα, CH, 1H, t, J = 7.43 Hz).  13C NMR (D2O) δ (ppm): 23.59 (Kγ, CH2), 24.56 
(R1γ, CH2), 24.81 (Rγ, CH2), 29.8 (Kδ, CH2), 29.18 (R1β, CH2), 29.27 (Rβ, CH2), 31.56 (Kβ, 
CH2), 40.46 (R1δ, CH2), 41.50 (Rδ, CH2), 41.61 (Kε, CH2), 43.19 (Gα, CH2), 43.58 (G1α, CH2), 
43.65 (G2α, CH2), 53.71 (R1α, CH), 54.14 (Rα, CH), 55.45 (Kα, CH), 158.01 (R2, R12, C=NH), 
170.45 - 170.91 (R, R1, C=O), 173.10 (G1-2, G, C=O), 175.49 (K, C=O).  Yield: 0.065 g (65 %).  
ESI
+
-MS m/z: (C24H48N14O6) calculated 628.39, found 629.50 [M + H]
+
.  Rt: 11.35 min.   
8
+
 Arginine (Figure. 1-3): Gly (3 equiv), Gly (2 equiv), Gly (2 equiv), Lys (2 equiv), Lys (3 
equiv), Arg (6 equiv).  The same process was followed as outlined for 4
+
 Arginine above.  
1
H 
NMR (D2O) δ (ppm): 1.23 – 1.83 (Kγ, K1-2γ, Kδ, K1-2δ, Rγ, R1-3γ, Kβ, K1-2β, Rβ, R1-3β, CH2, 
34H, m), 3.06 – 3.13 (Kε, K1-2ε, Rδ, R1-3δ, CH2, 14H, m), 3.82 (Gα, CH2, 2H, s), 3.90 (G1-2α, 
CH2, R1-3α, CH, 6H, s), 3.95 – 4.00 (Rα, CH, 2H, m), 4.11 – 4.22 (K1-2α, Kα, CH, 3H, t, J = 7.30 
Hz).  
13
C NMR (D2O) δ (ppm): 23.62 - 23.75 (Kγ, K1-2γ, CH2), 24.65 - 24.81 (Rγ, R1-3γ, CH2), 
28.98 - 29.26 (Rβ, R1-3β, Kδ, K1-2δ, CH2), 31.67 - 31.74 (Kβ, K1-2β, CH2), 40.29 - 40.50 (Rδ, R1-
3δ, CH2), 41.49 - 41.62 (Kε, K1-2ε, CH2), 43.23 - 43.72 (Gα, G1-2α, CH2), 53.71 (R1&3α, CH), 
54.14 (Rα, R2α, CH), 55.10 (K2α, CH), 55.28 (K1α, CH), 55.67 (Kα, CH), 158.01 (R, R1-32, 
C=NH), 170.45 - 170.77 (R, R1-2, C=O), 173.17 - 173.19 (G, G1-2, C=O), 174.57 (K2, C=O), 
174.91 (R3, C=O), 175.33 (K, C=O), 175.75 (K1, C=O).  Yield: 0.063 g (63 %).  ESI
+
-MS m/z: 
(C48H96N26O10) calculated 1197.44, found 1198.00 [M + H]
+
.  Rt: 13.28 min.   
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4
+
 Lysine (Figure. 1-4): Gly (3 equiv), Gly (2 equiv), Gly (2 equiv), Lys (2 equiv), Lys (3 equiv).  
The same process was followed as outlined for 4
+
 Arginine above.  
1
H NMR (D2O) δ (ppm): 
1.21 – 1.85 (Kγ, K1-2γ, Kδ, K1-2δ, Kβ, K1-2β, CH2, 18H, m), 2.86 – 2.89 (K1-2ε, CH2, 4H, m), 3.10 
– 3.13 (Kε, CH2, 2H, t, J = 7.18 Hz), 3.77 – 3.93 (K1-2α, CH, Gα, G1-2α, CH2, 8H, m), 4.21 – 4.24 
(Kα, CH, 1H, t, J = 7.18 Hz).  
13
C NMR (D2O) δ (ppm): 22.25 (K1γ, CH2), 22.56 (K2γ, CH2), 
23.58 (Kγ, CH2), 27.60 (K1δ, K2δ, CH2), 29.11 (Kδ, CH2), 31.60 (K1-2β, CH2), 31.65 (Kβ, CH2), 
40.20 (K1-2ε, CH2), 40.48 (Kε, CH2), 43.18 (Gα, CH2), 43.56 (G1α, CH2), 43.65 (G2α, CH2), 
53.93 (K2α, CH2), 54.35 (K1α, CH), 55.39 (Kα, CH), 170.55 – 170.95 (K1-2, C=O), 173.06 – 
173.14 (G, G1-2, C=O), 175.33 – 175.40 (K, C=O).  Yield: 0.083 g (83 %).  ESI
+
-MS m/z: 
(C24H48N10O6) calculated 572.70, found 573.50 [M + H]
+
.  Rt: 10.29 min.    
8
+
 Lysine (Figure. 1-5): Gly (3 equiv), Gly (2 equiv), Gly (2 equiv), Lys (2 equiv), Lys (3 equiv), 
Lys (5 equiv).  The same process was followed as outlined for 4
+
 Arginine above.  
1
H NMR 
(D2O) δ (ppm): 1.25 – 1.79 (Kγ, K1-6γ, Kδ, K1-6δ, Kβ, K1-6β, CH2, 42H, m), 2.86 – 2.91 (K1-6ε, 
CH2, 12H, q), 3.08 – 3.11 (Kε, CH2, 2H, m), 3.81 – 3.91 (K3-6α, CH, Gα, G1α, G2α, CH2, 10H, m), 
4.11 (K2α, CH, 1H, t, J = 7.01 Hz), 4.15 (K1α, CH, 1H, t, J = 7.01 Hz), 4.22 (Kα, CH, 1H, t, J = 
7.25 Hz).  
13
C NMR (D2O) δ (ppm): 22.38 - 22.57 (K1-6γ, CH2), 23.67 - 23.76 (Kγ, CH2), 27.56 - 
27.59 (K1-6δ, CH2), 29.16 - 29.22 (Kδ, CH2), 31.60 - 31.98 (Kβ, K1-6β, CH2), 40.20 - 40.54 (Kε, 
K1-6ε, CH2), 43.21 - 43.70 (Gα, G1-2α, CH2), 53.95 (K4&6α, CH), 54.36 (K3&5α, CH), 54.98 (Kα, 
CH), 55.36 (K1α, CH), 55.51(K2α, CH), 170.53 - 170.82 (K1, C=O), 173.11 (G, G1-2, C=O), 
174.40 (K2, C=O), 174.81 (K, C=O), 175.29 (K3&5, C=O), 175.70 (K4&6, C=O).  Yield: 0.062 g 
(62 %).  ESI
+
-MS m/z: (C48H96N18O10) calculated 1085.39, found 1086.00 [M + H]
+
.  Rt: 13.10 
min.   
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Plasmid preparation  
E .coli were transformed with a 4.3 kb plasmid (pEGFP-C1) encoding green fluorescent protein 
under control of a CMV promoter and grown in Luria broth (37°C, 16 h) on a shaker at 300 rpm.  
Plasmid DNA was recovered using an endotoxin-free megaprep kit (Qiagen).  DNA 
concentration was determined by UV absorbance at 260 and 280 nm after redissolving in water.   
 Ethidium bromide assay 
DNA (pEGFP-C1, 0.2 µg) was mixed with dendrimer (1 mg/ml) at various N:P ratios in distilled 
water and incubated for 30 min at room temperature.  After 30 min, ethidium bromide (EtBr) 
added at an EtBr:DNA base pair ratio of 1:4 [31].  Fluorescence was measured (either 485 nm 
Ex, 590 nm Em or 544 nm Ex and 590 nm Em) using a FLUOstar Optima microplate reader 
(BMG Labtech Pty. Ltd., Victoria, Australia).    
Transmission electron microscopy (TEM) 
Dendrimer/DNA complexes were prepared as described above and, at defined times after 
mixing, stained as previously described [32].  Briefly, 400 mesh formvar-free carbon coated 
grids were glow discharged for 30 sec.  A 5 µl drop of dendrimer/DNA complex solution was 
carefully placed on the grid and immediately stained with 1 % uranyl acetate and 15 – 30 sec 
later excess liquid was wicked off with filter paper.  Grids were air-dried prior to viewing (JEM 
– 1010 JEOL, Tokyo, 100 kV), images were captured using a digital camera (SoftImaging® 
Megaview III) and analysed using SoftImaging
®
.  
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Cytotoxicity assay 
Human embryonic kidney 293T cells were grown in culture medium (DMEM 10 % FCS) and 
seeded in a 24-well plate (3 × 10
6
/well) in 500 µl of medium.  Cells were incubated overnight 
(37°C, 5 % CO2) to reach 50 – 60 % confluency.  Dendrimer/DNA complexes were prepared as 
described above and after 30 min incubation the solution was made isotonic by addition of 1/10 
volume of 10 × PBS.  The medium was then replaced by 500 µl of fresh culture medium and 
isotonic dendrimer solution.  After a further 4 h, the dendrimer/DNA solution was replaced with 
fresh culture medium and cells cultured for a further 24 h.  Lipofectamine
®
 transfection was 
performed according to manufacturer’s instructions and cultured for 24 h total.  Non-adherent 
cells were harvested and pooled with adherent cells recovered by trypsinisation.  Viability was 
assessed by flow cytometry (BD FACScalibur
TM
) after staining with propidium iodide.   
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Results 
Synthesis and characterization of asymmetric dendrimers  
Asymmetric dendrimers with 4 or 8 terminal amines constructed with either arginine (‘4+ 
Arginine’, ‘8+ Arginine’) or lysine (‘4+ Lysine’, ‘8+ Lysine’) terminal amino acids (Figure. 1-2 - 
1-5) were synthesized using Fmoc SPPS.  After purification using preparative RP-HPLC, all 
dendrimers were obtained in good yield (60 – 85 %).  The molecular weight of each dendrimer 
was confirmed by ESI
+
-MS where the molecular ion of the dendrimer was identified.  Both 1D 
and 2D NMR spectroscopy (
1
H and 
13
C) were used for definitive assignments, although given 
the complexity of spectra for the arginine dendrimers in particular; 
1
H and 
13
C NMR of L-
arginine alone were also undertaken.  The data confirmed successful synthesis of the panel of 
asymmetric dendrimers (Figure. 1-2 - 1-5 and supporting information). 
Assessment of DNA complexation using ethidium bromide fluorescence 
Ethidium bromide dye fluoresces when intercalated with DNA.  As EtBr is prevented from 
intercalating with DNA in the presence of a complexing polycation, loss of fluorescence is a 
convenient measure of polycation/DNA complexation.  Based on loss of fluorescence, PAMAM 
G1 effectively complexed DNA at N:P ratios ≥ 0.5:1 (Figure. 2A).  Of the four asymmetric 
dendrimers, 8
+
 Arginine and 4
+
 Arginine complexed DNA with the most reproducible results and 
at N:P ratios as low as 5:1 (Figure. 2B and 2D).  8
+
 Lysine complexed DNA less reproducibly 
and at N:P ratios ≥ 5:1, whereas 4+ Lysine least reproducibly complexed DNA (Figure. 2C and 
2E).  Overall, asymmetric dendrimers constructed with arginine as the terminal amino acid 
complexed DNA more reproducibly, and at lower N:P ratios than those with lysine as the 
terminal amino acid. 
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Asymmetric dendrimers form toroidal complexes with DNA 
Transmission electron microscopy (TEM) was used to characterize the morphology of 
dendrimer/DNA complexes.  Our aim was to investigate whether toroidal structures were formed 
as these have been reported as characteristic of DNA complexation in other polycationic systems 
[33,34].  For these studies we chose to compare 8
+
 Arginine, which possessed the best DNA 
complexing characteristics in the EtBr assay, with PAMAM G1.  At a 1:1 N:P ratio of PAMAM 
G1 to DNA, we observed a meshwork of pleiomorphic structures (Figure. 3A).  As the N:P ratio 
was increased to 5:1, individual rod and toroid-like structures, which often formed small clusters 
of two to three rods or toroids, were observed (Figure. 3B).  At a 10:1 N:P ratio, individual 
toroids, which rarely formed clusters, were observed (Figure. 3C) and structures that resembled 
elongated or distorted toroids were frequently present, whilst rod-like structures were rarely 
observed.  Of the PAMAM G1/DNA complexes formed at a 10:1 N:P ratio approximately 40 % 
were individual toroids ranging between 35 and 110 nm and had a mean diameter of 61 ± 14 nm 
(mean ± SD).  We next determined the morphology of dendrimer/DNA complexes formed by 8
+
 
Arginine.  At a 1:1 N:P ratio, an extensive netted or meshwork structure was observed (Figure. 
3D) similar to that seen with PAMAM G1 at this ratio (Figure. 3A).  At a 5:1 N:P ratio elongated 
and segmented structures were observed (Figure. 3E), whereas at 10:1 toroid-like structures, 
present almost exclusively in clusters, were observed (Figure. 3F).  Of 8
+
 Arginine/DNA 
complexes formed at a 10:1 N:P ratio, approximately 46 % comprised clusters of toroids and 15 
% comprised individual toroids with a mean diameter 67 ± 17 nm (mean ± SD).  For both 
PAMAM G1 and 8
+
 Arginine, observed complexes not exhibiting a toroidal appearance were 
either elongated and distorted toroids or pleiomorphic in shape.  
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To better understand the behaviour and stability of dendrimer/DNA complexes, a time-course 
study was performed comparing PAMAM G1 and 8
+
 Arginine where morphology was observed 
10, 20, 30, 45, 60 and 120 min after addition of DNA to dendrimers at a 10:1 N:P ratio.  Between 
10 and 30 min, PAMAM G1/DNA comprised primarily toroids with few rods (see Table 1).  The 
proportion of rods then increased and outnumbered toroids at 60 and 120 min (see Table 1).  For 
8
+
 Arginine/DNA at a 10:1 N:P ratio, we observed clusters of toroids and this changed little over 
time, however, toroids appeared most numerous between 20 and 30 min after DNA/dendrimer 
mixing (see Table 2).  Overall, both PAMAM G1/DNA and 8
+
 Arginine/DNA formed ‘toroidal’ 
structures at all time points tested.  However, 8
+
 Arginine/DNA showed a disposition to form 
clusters of toroids whereas PAMAM G1/DNA formed individual toroids.  Based on the time-
course study, complexes between DNA and asymmetric dendrimers formed toroids that were 
stable over the time period tested.    
Asymmetric dendrimers effectively complex DNA in physiological salt solutions  
For effective gene transfer in vitro or in vivo, dendrimer/DNA complexes must be stable in 
physiological salt solutions.  Therefore, we next established whether ions present in phosphate 
buffer (PB) or sodium chloride-containing phosphate buffered saline (PBS) could interfere with 
dendrimer/DNA complexation.  To this end, the EtBr assay was used to compare complexation 
of DNA by dendrimers in saline, PB and PBS.  When complexed in saline and PB, PAMAM G1 
inhibited EtBr fluorescence indicating complex formation whereas complexes formed in PBS 
inhibited EtBr fluorescence only when a high N:P ratio of 50:1 was used (Figure. 4A).  
Similarly, 8
+
 Arginine effectively complexed DNA in water, saline and PB as indicated by the 
EtBr assay (Figure. 4B).  Likewise, for 8
+
 Arginine in PBS, EtBr fluorescence was inhibited 
when a high N:P ratio of 100:1 was tested signifying efficient complexation.  This data suggests 
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that counter-ions present within the solvent influence DNA complexation by asymmetric 
dendrimers and that the presence of the ions in PBS hinders effective complexation at low N:P 
ratios.  
Asymmetric dendrimer/DNA complexes exhibit minimal cytotoxicity 
To establish the cytotoxicity profile, DNA complexed with PAMAM, asymmetric dendrimers or 
Lipofectamine
®
 were incubated with HEK 293T cells for 4 h and cell viability was tested using a 
FACS-based propidium iodide assay a further 20 h later.  PAMAM G1/DNA complexes 
exhibited minimal toxicity to HEK 293T cells at all N:P ratios tested up to 100:1 (Figure. 5).  
This was in distinct contrast to Lipofectamine
®
, which killed approximately 40 % of cells under 
the same conditions.  A higher generation PAMAM dendrimer (G4) was also tested at an N:P 
ratio of 10:1 and this resulted in approximately 20 % cell death which increased to 
approximately 60 % when the N:P ratio was increased to 100:1(data not shown).  In contrast, 8
+
 
Arginine/DNA at all N:P ratios tested (≤ 100:1 N:P ratio) showed low cytotoxicity with cell 
viabilities in the range of 90 – 98 % observed (Figure. 5).  The data suggests that even at high 
N:P ratios required for complete complexation of DNA, low generation asymmetric peptide 
dendrimers display negligible cytotoxicity.  
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Discussion 
In vivo use of commercially-available high-generation (G4-G10) PAMAM and other spherical 
dendrimers is limited by cytotoxicity due to their high cationic charge density, while attempts to 
functionalize these systems with targeting moieties unavoidably generates heterogeneous end-
products.  We propose that low-generation asymmetric dendrimers, which are devoid of 
cytotoxicity and that permit site-specific attachment of a targeting ligand, distal to the site of 
DNA complexation would be a viable alternative to currently-available symmetrical dendrimers.  
We report the synthesis and characterisation of novel asymmetric low-generation dendrimers that 
effectively complex DNA and exhibit low cytotoxicity, even when complexed with DNA at high 
N:P ratios.   
Fmoc-based SPPS, a relatively simple and cost-effective synthesis method was used to construct 
the asymmetric dendrimers and post-synthesis analysis by ESI
+
-MS and NMR spectra confirmed 
that the dendrimers synthesized corresponded to the intended structures shown in Figure. 1 (1-2 
– 1-5).  We conclude that the results of the EtBr assay and TEM imaging indicate that, dependent 
on the number and nature of terminal amines, low-generation asymmetric dendrimers can 
effectively complex plasmid DNA with 8
+
 Arginine in particular, most efficiently complexing 
DNA.    
The TEM study performed here showed the presence of clusters of toroids formed by 8
+
 
Arginine/DNA.  This is consistent with previous demonstrations that toroids form upon 
polycation and DNA complexation [32,35-39] and these generally range from approximately 40 
to 90 nm in diameter [36,37,40].  We selected a wider range (35 to 110 nm) here to ensure all 
toroids that fell in the 40 – 90 nm ranges were included for quantitation.  In TEM images of 8+ 
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Arginine/DNA complexes, toroids existed primarily in clusters whereas PAMAM G1 formed 
primarily ‘non-clustering’ toroids.  Differences in the propensity to form ‘clustering’ toroids 
could be attributable to the marked differences in the physico-chemical properties of asymmetric 
and spherical dendrimers.  For example, asymmetric dendrimers, due to the potentially-fixed 
stereochemistry of amide bonds formed between the constituent amino acids and the ‘polarised’ 
nature of the molecule with terminal amines concentrated in the ‘head’ region, may permit more 
interaction between the ‘tails’ than is possible for spherical dendrimers which exhibit a more 
uniform arrangement of terminal amines.  Although there are reports of PAMAM G1 
complexing DNA this has been seen only when PAMAM G1 is used in conjunction with lipid or 
other cationic helper molecules [41-43].  To our knowledge, this is the first detailed report 
demonstrating formation of toroidal dendrimer/DNA complexes by PAMAM G1 in the absence 
of helper molecules.  The subtle irregularities in the size and shape of the toroids and rods we 
observed for dendrimer/DNA complexes are similar to those reported in the literature for other 
systems [37], and such variations in the morphology of dendrimer/DNA complexes appears 
normal.  Based on our time-course studies, we found that there was little difference in the 
morphology of dendrimer/DNA complexes across the time-points tested.  However, for 
PAMAM G1/DNA complexes a difference was noted in the proportion of rods to toroids which 
increased from 30 min after mixing of PAMAM and DNA.  This suggests the optimal incubation 
time for PAMAM G1/DNA complexes beyond which their morphology reverts to rods is around 
30 min.  On the other hand, with increasing time there was little difference in the morphology of 
8
+
 Arginine/DNA complexes suggesting an extended period of stability for these complexes, 
relative to PAMAM G1/DNA complexes.    
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For TEM, we tested 8
+
 Arginine/DNA at various N:P ratios (data not shown) but chose to work 
with an N:P ratio of 10:1 as at higher N:P ratios, the fixed concentration of DNA led to 
dendrimer/DNA complexes becoming more sparsely distributed on TEM grids.  Additionally, we 
also found that increasing dendrimer concentration above 1 mg/ml resulted in large-scale 
aggregation.  Although aggregation of dendrimer/DNA complexes has not been reported in TEM 
analysis, PAMAM dendrimers (≥ G1) have been shown to cause cell damage in vitro at 
concentrations greater than 1 mg/ml [12], and this may reflect findings similar to ours.  
Therefore, we conclude the optimal dendrimer concentration for forming complexes with DNA 
is 1 mg/ml for the asymmetric dendrimers tested here.    
A hierarchy of complexing effectiveness was observed among the arginine and lysine series of 
asymmetric dendrimers, with the arginine series complexing DNA with apparently greater 
affinity than lysine.  Others have reported similar or more efficient DNA complexation by 
arginine termini relative to lysine or other amino acids [44-46].  Arginine possesses a 
guanidinium moiety, which, with a pKa ≈ 13[47] is protonated over a wide pH range [48].  
Guanidinium groups and DNA form characteristic pairs of parallel hydrogen bonds that provide 
binding strength by their charge and structural organization.  These features are consistent with 
the demonstrated role for guanidinium groups in the arginine amino acid residues playing key 
roles in DNA-binding by proteins, such as histones.  Furthermore, due to it’s high pKa, arginine 
can also buffer the endosomal environment, a crucial factor in promoting release of DNA from 
endosomal compartment so transfection can take place [49].  Therefore, likely advantages of 
arginine-containing dendrimers are not only that DNA-binding should be relatively insensitive to 
pH variations during in vitro transfer and intracellular trafficking [48] but that they should also 
increase transfection efficiency. 
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We established that ions within the solvents used for asymmetric dendrimer/DNA complexation 
can adversely affect their formation.  Although a slight effect of PB or NaCl solutions was 
observed this was minor.  Interestingly, we noted that PBS, a reagent typically employed during 
in vitro studies inhibited dendrimer/DNA complexation at low N:P ratios.  However, this would 
be unlikely to affect the use of asymmetric dendrimers where physiological salt solutions are 
required as we demonstrated that complexes formed at a high N:P ratio did not result in 
dissociation of dendrimer from DNA.  Therefore, asymmetric dendrimers would be suitable for 
in vitro and in vivo use.   
Our data demonstrates that both low-generation asymmetric dendrimer/DNA complexes and 
PAMAM G1/DNA complexes exhibit low cytotoxicity.  These findings are consistent with a 
previous report in which PAMAM G1, but not higher generation (up to G4) PAMAM 
dendrimers exhibited little cytotoxicity in vitro [12].  Overall, and in general, specifically for 
asymmetric dendrimers, low generation dendrimers exhibit low cytotoxicity.  An important 
safety advantage of asymmetric dendrimers described here is that, asymmetric dendrimers will 
be degraded to harmless natural amino acids, whereas PAMAM dendrimers, upon degradation, 
may form toxic methacrylates.   
In conclusion, the studies described here demonstrate that peptidic asymmetric dendrimers can 
be constructed with ease, exhibit minimal cytotoxicity and effectively complex DNA.  We 
propose that peptidic asymmetric dendrimer/DNA complexes engineered using SPPS are a new 
dendrimer family that, when suitably modified and targeted by a range of ligands, will be an 
effective system for efficient and safe DNA delivery in vivo.           
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Abbreviations  
DNA – deoxyribonucleic acid, siRNA – short interfering ribonucleic acid, PEG – poly (ethylene 
glycol), H2O – water, D2O – deuterium oxide, CH3CN – acetonitrile, HFBA – heptafluorobutyric 
acid, Fmoc – fluorenylmethoxycarbonyl, Pbf - 2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl, DCM – dichloromethane, TIPS – triisopropyl silane, Rt – retention time , FCS – foetal 
calf serum, PBS – phosphate buffer saline. 
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Table 1. Time-dependency of PAMAM G1/DNA complexation (10:1 N:P ratio). 
 
Incubation time 
(min) 
% toroids 
Mean diameter of 
toroids 
 (nm; mean ± SD) 
% rods 
10 16 64 ± 10 7 
20 32 64 ± 11 10 
30 35 69 ± 11 3 
45 26 62 ± 9 24 
60 25 67 ± 8 30 
120 21 79 ± 15 41 
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Table 2. Time-dependency of 8
+
 Arginine/DNA complexation (10:1 N:P ratio). 
 
Incubation time 
(min) 
% toroids 
Mean diameter of 
toroids 
 (nm; mean ± SD) 
% rods 
10 27 80 ± 14 0 
20 35 68 ± 16 0 
30 35 74 ± 13 0 
45 27 71 ± 15 0 
60 22 76 ± 15 0 
120 20 81 ± 13 0 
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LEGEND TO FIGURES 
  
Figure. 1. Structure of PAMAM G11, 4
+
 Arginine 2, 8
+
 Arginine 3, 4
+
Lysine 4 and 8
+
 Lysine 5 
dendrimers. 
Figure. 2. EtBr assay indicates effective DNA complexation by asymmetric dendrimers.  
Dendrimers were complexed with DNA in either baxter or autoclaved milli Q water at increasing 
N:P ratio and equilibrated with EtBr:DNA at a base pair ratio of 1:4.  Fluorescence was 
measured at 485 nm (Ex) and 590 nm (Em) or 544 nm (Ex) and 590 nm (Em) for triplicate 
samples in each assay and the relative fluorescence intensity calculated.  Data from 2-4 separate 
experiments are shown as mean and SD of triplicate samples at each N:P ratio. 
Figure. 3. The difference in morphology of the structures indicates development of toroids at 
increasing N:P ratio.  Dendrimer/DNA complexes were prepared in water (30 min incubation) 
and visualised by transmission electron microscopy.  A - C) PAMAM G1 1:1, 5:1 and 10:1 N:P 
ratios respectively, D - F) 8
+
 Arginine at 1:1, 5:1 and 10:1 N:P ratios respectively.  Images are 
representative of at least 10 sampled fields of view from each of 3 independent experiments 
carried out at each N:P ratio. 
Figure. 4. Dendrimer/DNA complexation is altered by the presence of sodium chloride ions.  To 
determine the role of ions present in solution, PAMAM G1/DNA complexes (A) and 8
+
 Arginine 
asymmetric dendrimer/DNA complexes (B) were prepared in different buffers and DNA 
complexation tested using the EtBr assay.  Data (mean ± SD) are pooled from atleast 2 
independent experiments in which samples were tested in triplicate. 
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Figure. 5. Low generation dendrimers exhibit minimal toxicity.  Dendrimer/DNA complexes 
were prepared in water at defined N:P ratios, incubated for 30 min and then made isotonic by 
addition of 10 × PBS.  Dendrimer/DNA complexes were then incubated with HEK 293T cells 
and cell viability assessed by propidium iodide staining 24 h later.  Data (mean ± SD) are pooled 
from 3 independent experiments.  Controls are untreated cells (control), cells incubated with 
DNA alone (DNA) or cells treated under identical conditions with DNA/Lipofectamine
®
 
complexes (Lipofectamine).   
 
 




